Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I
Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.Material and methods. We performed the analysis of outpatient records of 1000 patients, followed up for 1 year by a general practitione...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Yu. M. Lopatin [verfasserIn] S. V. Nedogoda [verfasserIn] M. V. Arkhipov [verfasserIn] A. S. Galyavich [verfasserIn] N. A. Koziolova [verfasserIn] N. G. Lozhkina [verfasserIn] E. V. Reznik [verfasserIn] A. S. Salasyuk [verfasserIn] M. Yu. Frolov [verfasserIn] A. I. Chesnikova [verfasserIn] E. V. Chumachek [verfasserIn] L. A. Shpagina [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Российский кардиологический журнал - «FIRMA «SILICEA» LLC, 2019, 26(2021), 4 |
|---|---|
| Übergeordnetes Werk: |
volume:26 ; year:2021 ; number:4 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.15829/1560-4071-2021-4368 |
|---|
| Katalog-ID: |
DOAJ030680166 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ030680166 | ||
| 003 | DE-627 | ||
| 005 | 20230410123320.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.15829/1560-4071-2021-4368 |2 doi | |
| 035 | |a (DE-627)DOAJ030680166 | ||
| 035 | |a (DE-599)DOAJ69da45f5a9f2442abd4c2790d12db976 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RC666-701 | |
| 100 | 0 | |a Yu. M. Lopatin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.Material and methods. We performed the analysis of outpatient records of 1000 patients, followed up for 1 year by a general practitioner or cardiologist in ambulatory clinic in 7 Russian regions. The study included men and women over 18 years of age with an established class II-IV HF and at least one hospitalization due to acute decompensated HF within 12-month follow-up.Results. The final analysis included 888 patients (men, 52,9%; women, 47,1%; mean age, 69 [61; 78] years). The preserved ejection fraction (EF) was detected in 47,86% of patients, mid-range — in 40,54%, reduced — in 11,6%. Only in 16% of patients, there was improved by 1 or more HF. Hypertension and coronary artery disease were predominant in etiology pattern of HF. Preserved EF was more often detected in women over 60 years of age, with HTN and obesity, as well as with HF with mid-range and reduced EF in men in the same age group. There was sufficient follow-up rate, but the extent examinations do not correspond to the recommended one. The prescription rate of renin-angiotensin-aldosterone system (RAAS) inhibitors corresponds to the recommended one, but there is a high frequency of prescribing angiotensin II receptor blockers (ARBs). The prescription rate of β-blockers and loop diuretics (mainly torasemide) increased in comparison with previous studies, while thiazide diuretics — decreased. In patients with reduced EF, the prescription rate of sacubitril/valsartan was only 14,7%, β-blockers — 83,3%, mineralocorticoid receptor antagonists (MCRA) — 72,5%. In patients with midrange EF, there was a sharp decrease in prescription rate of RAAS inhibitors, β-blockers, MCRA.Conclusion. The practical follow-up of patients with HF differs significantly from clinical guidelines. Due to inadequate pharmacotherapy, as well as insufficient noncompliance with the recommended extent of investigations, 1-year HF therapy does not lead to a pronounced improvement in the patients' class. | ||
| 650 | 4 | |a pharmacoepidemiology | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a left ventricular ejection fraction | |
| 650 | 4 | |a functional class | |
| 653 | 0 | |a Diseases of the circulatory (Cardiovascular) system | |
| 700 | 0 | |a S. V. Nedogoda |e verfasserin |4 aut | |
| 700 | 0 | |a M. V. Arkhipov |e verfasserin |4 aut | |
| 700 | 0 | |a A. S. Galyavich |e verfasserin |4 aut | |
| 700 | 0 | |a N. A. Koziolova |e verfasserin |4 aut | |
| 700 | 0 | |a N. G. Lozhkina |e verfasserin |4 aut | |
| 700 | 0 | |a E. V. Reznik |e verfasserin |4 aut | |
| 700 | 0 | |a A. S. Salasyuk |e verfasserin |4 aut | |
| 700 | 0 | |a M. Yu. Frolov |e verfasserin |4 aut | |
| 700 | 0 | |a A. I. Chesnikova |e verfasserin |4 aut | |
| 700 | 0 | |a E. V. Chumachek |e verfasserin |4 aut | |
| 700 | 0 | |a L. A. Shpagina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Российский кардиологический журнал |d «FIRMA «SILICEA» LLC, 2019 |g 26(2021), 4 |w (DE-627)1760594547 |x 26187620 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2021 |g number:4 |
| 856 | 4 | 0 | |u https://doi.org/10.15829/1560-4071-2021-4368 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/69da45f5a9f2442abd4c2790d12db976 |z kostenfrei |
| 856 | 4 | 0 | |u https://russjcardiol.elpub.ru/jour/article/view/4368 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1560-4071 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2618-7620 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2021 |e 4 | ||
| author_variant |
y m l yml s v n svn m v a mva a s g asg n a k nak n g l ngl e v r evr a s s ass m y f myf a i c aic e v c evc l a s las |
|---|---|
| matchkey_str |
article:26187620:2021----::hraopdmooiaaayioruieaaeetferfiueains |
| hierarchy_sort_str |
2021 |
| callnumber-subject-code |
RC |
| publishDate |
2021 |
| allfields |
10.15829/1560-4071-2021-4368 doi (DE-627)DOAJ030680166 (DE-599)DOAJ69da45f5a9f2442abd4c2790d12db976 DE-627 ger DE-627 rakwb rus RC666-701 Yu. M. Lopatin verfasserin aut Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.Material and methods. We performed the analysis of outpatient records of 1000 patients, followed up for 1 year by a general practitioner or cardiologist in ambulatory clinic in 7 Russian regions. The study included men and women over 18 years of age with an established class II-IV HF and at least one hospitalization due to acute decompensated HF within 12-month follow-up.Results. The final analysis included 888 patients (men, 52,9%; women, 47,1%; mean age, 69 [61; 78] years). The preserved ejection fraction (EF) was detected in 47,86% of patients, mid-range — in 40,54%, reduced — in 11,6%. Only in 16% of patients, there was improved by 1 or more HF. Hypertension and coronary artery disease were predominant in etiology pattern of HF. Preserved EF was more often detected in women over 60 years of age, with HTN and obesity, as well as with HF with mid-range and reduced EF in men in the same age group. There was sufficient follow-up rate, but the extent examinations do not correspond to the recommended one. The prescription rate of renin-angiotensin-aldosterone system (RAAS) inhibitors corresponds to the recommended one, but there is a high frequency of prescribing angiotensin II receptor blockers (ARBs). The prescription rate of β-blockers and loop diuretics (mainly torasemide) increased in comparison with previous studies, while thiazide diuretics — decreased. In patients with reduced EF, the prescription rate of sacubitril/valsartan was only 14,7%, β-blockers — 83,3%, mineralocorticoid receptor antagonists (MCRA) — 72,5%. In patients with midrange EF, there was a sharp decrease in prescription rate of RAAS inhibitors, β-blockers, MCRA.Conclusion. The practical follow-up of patients with HF differs significantly from clinical guidelines. Due to inadequate pharmacotherapy, as well as insufficient noncompliance with the recommended extent of investigations, 1-year HF therapy does not lead to a pronounced improvement in the patients' class. pharmacoepidemiology heart failure left ventricular ejection fraction functional class Diseases of the circulatory (Cardiovascular) system S. V. Nedogoda verfasserin aut M. V. Arkhipov verfasserin aut A. S. Galyavich verfasserin aut N. A. Koziolova verfasserin aut N. G. Lozhkina verfasserin aut E. V. Reznik verfasserin aut A. S. Salasyuk verfasserin aut M. Yu. Frolov verfasserin aut A. I. Chesnikova verfasserin aut E. V. Chumachek verfasserin aut L. A. Shpagina verfasserin aut In Российский кардиологический журнал «FIRMA «SILICEA» LLC, 2019 26(2021), 4 (DE-627)1760594547 26187620 nnns volume:26 year:2021 number:4 https://doi.org/10.15829/1560-4071-2021-4368 kostenfrei https://doaj.org/article/69da45f5a9f2442abd4c2790d12db976 kostenfrei https://russjcardiol.elpub.ru/jour/article/view/4368 kostenfrei https://doaj.org/toc/1560-4071 Journal toc kostenfrei https://doaj.org/toc/2618-7620 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 26 2021 4 |
| spelling |
10.15829/1560-4071-2021-4368 doi (DE-627)DOAJ030680166 (DE-599)DOAJ69da45f5a9f2442abd4c2790d12db976 DE-627 ger DE-627 rakwb rus RC666-701 Yu. M. Lopatin verfasserin aut Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.Material and methods. We performed the analysis of outpatient records of 1000 patients, followed up for 1 year by a general practitioner or cardiologist in ambulatory clinic in 7 Russian regions. The study included men and women over 18 years of age with an established class II-IV HF and at least one hospitalization due to acute decompensated HF within 12-month follow-up.Results. The final analysis included 888 patients (men, 52,9%; women, 47,1%; mean age, 69 [61; 78] years). The preserved ejection fraction (EF) was detected in 47,86% of patients, mid-range — in 40,54%, reduced — in 11,6%. Only in 16% of patients, there was improved by 1 or more HF. Hypertension and coronary artery disease were predominant in etiology pattern of HF. Preserved EF was more often detected in women over 60 years of age, with HTN and obesity, as well as with HF with mid-range and reduced EF in men in the same age group. There was sufficient follow-up rate, but the extent examinations do not correspond to the recommended one. The prescription rate of renin-angiotensin-aldosterone system (RAAS) inhibitors corresponds to the recommended one, but there is a high frequency of prescribing angiotensin II receptor blockers (ARBs). The prescription rate of β-blockers and loop diuretics (mainly torasemide) increased in comparison with previous studies, while thiazide diuretics — decreased. In patients with reduced EF, the prescription rate of sacubitril/valsartan was only 14,7%, β-blockers — 83,3%, mineralocorticoid receptor antagonists (MCRA) — 72,5%. In patients with midrange EF, there was a sharp decrease in prescription rate of RAAS inhibitors, β-blockers, MCRA.Conclusion. The practical follow-up of patients with HF differs significantly from clinical guidelines. Due to inadequate pharmacotherapy, as well as insufficient noncompliance with the recommended extent of investigations, 1-year HF therapy does not lead to a pronounced improvement in the patients' class. pharmacoepidemiology heart failure left ventricular ejection fraction functional class Diseases of the circulatory (Cardiovascular) system S. V. Nedogoda verfasserin aut M. V. Arkhipov verfasserin aut A. S. Galyavich verfasserin aut N. A. Koziolova verfasserin aut N. G. Lozhkina verfasserin aut E. V. Reznik verfasserin aut A. S. Salasyuk verfasserin aut M. Yu. Frolov verfasserin aut A. I. Chesnikova verfasserin aut E. V. Chumachek verfasserin aut L. A. Shpagina verfasserin aut In Российский кардиологический журнал «FIRMA «SILICEA» LLC, 2019 26(2021), 4 (DE-627)1760594547 26187620 nnns volume:26 year:2021 number:4 https://doi.org/10.15829/1560-4071-2021-4368 kostenfrei https://doaj.org/article/69da45f5a9f2442abd4c2790d12db976 kostenfrei https://russjcardiol.elpub.ru/jour/article/view/4368 kostenfrei https://doaj.org/toc/1560-4071 Journal toc kostenfrei https://doaj.org/toc/2618-7620 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 26 2021 4 |
| allfields_unstemmed |
10.15829/1560-4071-2021-4368 doi (DE-627)DOAJ030680166 (DE-599)DOAJ69da45f5a9f2442abd4c2790d12db976 DE-627 ger DE-627 rakwb rus RC666-701 Yu. M. Lopatin verfasserin aut Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.Material and methods. We performed the analysis of outpatient records of 1000 patients, followed up for 1 year by a general practitioner or cardiologist in ambulatory clinic in 7 Russian regions. The study included men and women over 18 years of age with an established class II-IV HF and at least one hospitalization due to acute decompensated HF within 12-month follow-up.Results. The final analysis included 888 patients (men, 52,9%; women, 47,1%; mean age, 69 [61; 78] years). The preserved ejection fraction (EF) was detected in 47,86% of patients, mid-range — in 40,54%, reduced — in 11,6%. Only in 16% of patients, there was improved by 1 or more HF. Hypertension and coronary artery disease were predominant in etiology pattern of HF. Preserved EF was more often detected in women over 60 years of age, with HTN and obesity, as well as with HF with mid-range and reduced EF in men in the same age group. There was sufficient follow-up rate, but the extent examinations do not correspond to the recommended one. The prescription rate of renin-angiotensin-aldosterone system (RAAS) inhibitors corresponds to the recommended one, but there is a high frequency of prescribing angiotensin II receptor blockers (ARBs). The prescription rate of β-blockers and loop diuretics (mainly torasemide) increased in comparison with previous studies, while thiazide diuretics — decreased. In patients with reduced EF, the prescription rate of sacubitril/valsartan was only 14,7%, β-blockers — 83,3%, mineralocorticoid receptor antagonists (MCRA) — 72,5%. In patients with midrange EF, there was a sharp decrease in prescription rate of RAAS inhibitors, β-blockers, MCRA.Conclusion. The practical follow-up of patients with HF differs significantly from clinical guidelines. Due to inadequate pharmacotherapy, as well as insufficient noncompliance with the recommended extent of investigations, 1-year HF therapy does not lead to a pronounced improvement in the patients' class. pharmacoepidemiology heart failure left ventricular ejection fraction functional class Diseases of the circulatory (Cardiovascular) system S. V. Nedogoda verfasserin aut M. V. Arkhipov verfasserin aut A. S. Galyavich verfasserin aut N. A. Koziolova verfasserin aut N. G. Lozhkina verfasserin aut E. V. Reznik verfasserin aut A. S. Salasyuk verfasserin aut M. Yu. Frolov verfasserin aut A. I. Chesnikova verfasserin aut E. V. Chumachek verfasserin aut L. A. Shpagina verfasserin aut In Российский кардиологический журнал «FIRMA «SILICEA» LLC, 2019 26(2021), 4 (DE-627)1760594547 26187620 nnns volume:26 year:2021 number:4 https://doi.org/10.15829/1560-4071-2021-4368 kostenfrei https://doaj.org/article/69da45f5a9f2442abd4c2790d12db976 kostenfrei https://russjcardiol.elpub.ru/jour/article/view/4368 kostenfrei https://doaj.org/toc/1560-4071 Journal toc kostenfrei https://doaj.org/toc/2618-7620 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 26 2021 4 |
| allfieldsGer |
10.15829/1560-4071-2021-4368 doi (DE-627)DOAJ030680166 (DE-599)DOAJ69da45f5a9f2442abd4c2790d12db976 DE-627 ger DE-627 rakwb rus RC666-701 Yu. M. Lopatin verfasserin aut Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.Material and methods. We performed the analysis of outpatient records of 1000 patients, followed up for 1 year by a general practitioner or cardiologist in ambulatory clinic in 7 Russian regions. The study included men and women over 18 years of age with an established class II-IV HF and at least one hospitalization due to acute decompensated HF within 12-month follow-up.Results. The final analysis included 888 patients (men, 52,9%; women, 47,1%; mean age, 69 [61; 78] years). The preserved ejection fraction (EF) was detected in 47,86% of patients, mid-range — in 40,54%, reduced — in 11,6%. Only in 16% of patients, there was improved by 1 or more HF. Hypertension and coronary artery disease were predominant in etiology pattern of HF. Preserved EF was more often detected in women over 60 years of age, with HTN and obesity, as well as with HF with mid-range and reduced EF in men in the same age group. There was sufficient follow-up rate, but the extent examinations do not correspond to the recommended one. The prescription rate of renin-angiotensin-aldosterone system (RAAS) inhibitors corresponds to the recommended one, but there is a high frequency of prescribing angiotensin II receptor blockers (ARBs). The prescription rate of β-blockers and loop diuretics (mainly torasemide) increased in comparison with previous studies, while thiazide diuretics — decreased. In patients with reduced EF, the prescription rate of sacubitril/valsartan was only 14,7%, β-blockers — 83,3%, mineralocorticoid receptor antagonists (MCRA) — 72,5%. In patients with midrange EF, there was a sharp decrease in prescription rate of RAAS inhibitors, β-blockers, MCRA.Conclusion. The practical follow-up of patients with HF differs significantly from clinical guidelines. Due to inadequate pharmacotherapy, as well as insufficient noncompliance with the recommended extent of investigations, 1-year HF therapy does not lead to a pronounced improvement in the patients' class. pharmacoepidemiology heart failure left ventricular ejection fraction functional class Diseases of the circulatory (Cardiovascular) system S. V. Nedogoda verfasserin aut M. V. Arkhipov verfasserin aut A. S. Galyavich verfasserin aut N. A. Koziolova verfasserin aut N. G. Lozhkina verfasserin aut E. V. Reznik verfasserin aut A. S. Salasyuk verfasserin aut M. Yu. Frolov verfasserin aut A. I. Chesnikova verfasserin aut E. V. Chumachek verfasserin aut L. A. Shpagina verfasserin aut In Российский кардиологический журнал «FIRMA «SILICEA» LLC, 2019 26(2021), 4 (DE-627)1760594547 26187620 nnns volume:26 year:2021 number:4 https://doi.org/10.15829/1560-4071-2021-4368 kostenfrei https://doaj.org/article/69da45f5a9f2442abd4c2790d12db976 kostenfrei https://russjcardiol.elpub.ru/jour/article/view/4368 kostenfrei https://doaj.org/toc/1560-4071 Journal toc kostenfrei https://doaj.org/toc/2618-7620 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 26 2021 4 |
| allfieldsSound |
10.15829/1560-4071-2021-4368 doi (DE-627)DOAJ030680166 (DE-599)DOAJ69da45f5a9f2442abd4c2790d12db976 DE-627 ger DE-627 rakwb rus RC666-701 Yu. M. Lopatin verfasserin aut Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.Material and methods. We performed the analysis of outpatient records of 1000 patients, followed up for 1 year by a general practitioner or cardiologist in ambulatory clinic in 7 Russian regions. The study included men and women over 18 years of age with an established class II-IV HF and at least one hospitalization due to acute decompensated HF within 12-month follow-up.Results. The final analysis included 888 patients (men, 52,9%; women, 47,1%; mean age, 69 [61; 78] years). The preserved ejection fraction (EF) was detected in 47,86% of patients, mid-range — in 40,54%, reduced — in 11,6%. Only in 16% of patients, there was improved by 1 or more HF. Hypertension and coronary artery disease were predominant in etiology pattern of HF. Preserved EF was more often detected in women over 60 years of age, with HTN and obesity, as well as with HF with mid-range and reduced EF in men in the same age group. There was sufficient follow-up rate, but the extent examinations do not correspond to the recommended one. The prescription rate of renin-angiotensin-aldosterone system (RAAS) inhibitors corresponds to the recommended one, but there is a high frequency of prescribing angiotensin II receptor blockers (ARBs). The prescription rate of β-blockers and loop diuretics (mainly torasemide) increased in comparison with previous studies, while thiazide diuretics — decreased. In patients with reduced EF, the prescription rate of sacubitril/valsartan was only 14,7%, β-blockers — 83,3%, mineralocorticoid receptor antagonists (MCRA) — 72,5%. In patients with midrange EF, there was a sharp decrease in prescription rate of RAAS inhibitors, β-blockers, MCRA.Conclusion. The practical follow-up of patients with HF differs significantly from clinical guidelines. Due to inadequate pharmacotherapy, as well as insufficient noncompliance with the recommended extent of investigations, 1-year HF therapy does not lead to a pronounced improvement in the patients' class. pharmacoepidemiology heart failure left ventricular ejection fraction functional class Diseases of the circulatory (Cardiovascular) system S. V. Nedogoda verfasserin aut M. V. Arkhipov verfasserin aut A. S. Galyavich verfasserin aut N. A. Koziolova verfasserin aut N. G. Lozhkina verfasserin aut E. V. Reznik verfasserin aut A. S. Salasyuk verfasserin aut M. Yu. Frolov verfasserin aut A. I. Chesnikova verfasserin aut E. V. Chumachek verfasserin aut L. A. Shpagina verfasserin aut In Российский кардиологический журнал «FIRMA «SILICEA» LLC, 2019 26(2021), 4 (DE-627)1760594547 26187620 nnns volume:26 year:2021 number:4 https://doi.org/10.15829/1560-4071-2021-4368 kostenfrei https://doaj.org/article/69da45f5a9f2442abd4c2790d12db976 kostenfrei https://russjcardiol.elpub.ru/jour/article/view/4368 kostenfrei https://doaj.org/toc/1560-4071 Journal toc kostenfrei https://doaj.org/toc/2618-7620 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 26 2021 4 |
| language |
Russian |
| source |
In Российский кардиологический журнал 26(2021), 4 volume:26 year:2021 number:4 |
| sourceStr |
In Российский кардиологический журнал 26(2021), 4 volume:26 year:2021 number:4 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
pharmacoepidemiology heart failure left ventricular ejection fraction functional class Diseases of the circulatory (Cardiovascular) system |
| isfreeaccess_bool |
true |
| container_title |
Российский кардиологический журнал |
| authorswithroles_txt_mv |
Yu. M. Lopatin @@aut@@ S. V. Nedogoda @@aut@@ M. V. Arkhipov @@aut@@ A. S. Galyavich @@aut@@ N. A. Koziolova @@aut@@ N. G. Lozhkina @@aut@@ E. V. Reznik @@aut@@ A. S. Salasyuk @@aut@@ M. Yu. Frolov @@aut@@ A. I. Chesnikova @@aut@@ E. V. Chumachek @@aut@@ L. A. Shpagina @@aut@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
1760594547 |
| id |
DOAJ030680166 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ030680166</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410123320.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2021 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.15829/1560-4071-2021-4368</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ030680166</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ69da45f5a9f2442abd4c2790d12db976</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Yu. M. Lopatin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.Material and methods. We performed the analysis of outpatient records of 1000 patients, followed up for 1 year by a general practitioner or cardiologist in ambulatory clinic in 7 Russian regions. The study included men and women over 18 years of age with an established class II-IV HF and at least one hospitalization due to acute decompensated HF within 12-month follow-up.Results. The final analysis included 888 patients (men, 52,9%; women, 47,1%; mean age, 69 [61; 78] years). The preserved ejection fraction (EF) was detected in 47,86% of patients, mid-range — in 40,54%, reduced — in 11,6%. Only in 16% of patients, there was improved by 1 or more HF. Hypertension and coronary artery disease were predominant in etiology pattern of HF. Preserved EF was more often detected in women over 60 years of age, with HTN and obesity, as well as with HF with mid-range and reduced EF in men in the same age group. There was sufficient follow-up rate, but the extent examinations do not correspond to the recommended one. The prescription rate of renin-angiotensin-aldosterone system (RAAS) inhibitors corresponds to the recommended one, but there is a high frequency of prescribing angiotensin II receptor blockers (ARBs). The prescription rate of β-blockers and loop diuretics (mainly torasemide) increased in comparison with previous studies, while thiazide diuretics — decreased. In patients with reduced EF, the prescription rate of sacubitril/valsartan was only 14,7%, β-blockers — 83,3%, mineralocorticoid receptor antagonists (MCRA) — 72,5%. In patients with midrange EF, there was a sharp decrease in prescription rate of RAAS inhibitors, β-blockers, MCRA.Conclusion. The practical follow-up of patients with HF differs significantly from clinical guidelines. Due to inadequate pharmacotherapy, as well as insufficient noncompliance with the recommended extent of investigations, 1-year HF therapy does not lead to a pronounced improvement in the patients' class.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pharmacoepidemiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">left ventricular ejection fraction</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">functional class</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. V. Nedogoda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. V. Arkhipov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. S. Galyavich</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. A. Koziolova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. G. Lozhkina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Reznik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. S. Salasyuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Yu. Frolov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. I. Chesnikova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Chumachek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. A. Shpagina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Российский кардиологический журнал</subfield><subfield code="d">«FIRMA «SILICEA» LLC, 2019</subfield><subfield code="g">26(2021), 4</subfield><subfield code="w">(DE-627)1760594547</subfield><subfield code="x">26187620</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.15829/1560-4071-2021-4368</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/69da45f5a9f2442abd4c2790d12db976</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://russjcardiol.elpub.ru/jour/article/view/4368</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1560-4071</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-7620</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Yu. M. Lopatin |
| spellingShingle |
Yu. M. Lopatin misc RC666-701 misc pharmacoepidemiology misc heart failure misc left ventricular ejection fraction misc functional class misc Diseases of the circulatory (Cardiovascular) system Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I |
| authorStr |
Yu. M. Lopatin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760594547 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC666-701 |
| illustrated |
Not Illustrated |
| issn |
26187620 |
| topic_title |
RC666-701 Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I pharmacoepidemiology heart failure left ventricular ejection fraction functional class |
| topic |
misc RC666-701 misc pharmacoepidemiology misc heart failure misc left ventricular ejection fraction misc functional class misc Diseases of the circulatory (Cardiovascular) system |
| topic_unstemmed |
misc RC666-701 misc pharmacoepidemiology misc heart failure misc left ventricular ejection fraction misc functional class misc Diseases of the circulatory (Cardiovascular) system |
| topic_browse |
misc RC666-701 misc pharmacoepidemiology misc heart failure misc left ventricular ejection fraction misc functional class misc Diseases of the circulatory (Cardiovascular) system |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Российский кардиологический журнал |
| hierarchy_parent_id |
1760594547 |
| hierarchy_top_title |
Российский кардиологический журнал |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760594547 |
| title |
Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I |
| ctrlnum |
(DE-627)DOAJ030680166 (DE-599)DOAJ69da45f5a9f2442abd4c2790d12db976 |
| title_full |
Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I |
| author_sort |
Yu. M. Lopatin |
| journal |
Российский кардиологический журнал |
| journalStr |
Российский кардиологический журнал |
| callnumber-first-code |
R |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| author_browse |
Yu. M. Lopatin S. V. Nedogoda M. V. Arkhipov A. S. Galyavich N. A. Koziolova N. G. Lozhkina E. V. Reznik A. S. Salasyuk M. Yu. Frolov A. I. Chesnikova E. V. Chumachek L. A. Shpagina |
| container_volume |
26 |
| class |
RC666-701 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Yu. M. Lopatin |
| doi_str_mv |
10.15829/1560-4071-2021-4368 |
| author2-role |
verfasserin |
| title_sort |
pharmacoepidemiological analysis of routine management of heart failure patients in the russian federation. part i |
| callnumber |
RC666-701 |
| title_auth |
Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I |
| abstract |
Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.Material and methods. We performed the analysis of outpatient records of 1000 patients, followed up for 1 year by a general practitioner or cardiologist in ambulatory clinic in 7 Russian regions. The study included men and women over 18 years of age with an established class II-IV HF and at least one hospitalization due to acute decompensated HF within 12-month follow-up.Results. The final analysis included 888 patients (men, 52,9%; women, 47,1%; mean age, 69 [61; 78] years). The preserved ejection fraction (EF) was detected in 47,86% of patients, mid-range — in 40,54%, reduced — in 11,6%. Only in 16% of patients, there was improved by 1 or more HF. Hypertension and coronary artery disease were predominant in etiology pattern of HF. Preserved EF was more often detected in women over 60 years of age, with HTN and obesity, as well as with HF with mid-range and reduced EF in men in the same age group. There was sufficient follow-up rate, but the extent examinations do not correspond to the recommended one. The prescription rate of renin-angiotensin-aldosterone system (RAAS) inhibitors corresponds to the recommended one, but there is a high frequency of prescribing angiotensin II receptor blockers (ARBs). The prescription rate of β-blockers and loop diuretics (mainly torasemide) increased in comparison with previous studies, while thiazide diuretics — decreased. In patients with reduced EF, the prescription rate of sacubitril/valsartan was only 14,7%, β-blockers — 83,3%, mineralocorticoid receptor antagonists (MCRA) — 72,5%. In patients with midrange EF, there was a sharp decrease in prescription rate of RAAS inhibitors, β-blockers, MCRA.Conclusion. The practical follow-up of patients with HF differs significantly from clinical guidelines. Due to inadequate pharmacotherapy, as well as insufficient noncompliance with the recommended extent of investigations, 1-year HF therapy does not lead to a pronounced improvement in the patients' class. |
| abstractGer |
Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.Material and methods. We performed the analysis of outpatient records of 1000 patients, followed up for 1 year by a general practitioner or cardiologist in ambulatory clinic in 7 Russian regions. The study included men and women over 18 years of age with an established class II-IV HF and at least one hospitalization due to acute decompensated HF within 12-month follow-up.Results. The final analysis included 888 patients (men, 52,9%; women, 47,1%; mean age, 69 [61; 78] years). The preserved ejection fraction (EF) was detected in 47,86% of patients, mid-range — in 40,54%, reduced — in 11,6%. Only in 16% of patients, there was improved by 1 or more HF. Hypertension and coronary artery disease were predominant in etiology pattern of HF. Preserved EF was more often detected in women over 60 years of age, with HTN and obesity, as well as with HF with mid-range and reduced EF in men in the same age group. There was sufficient follow-up rate, but the extent examinations do not correspond to the recommended one. The prescription rate of renin-angiotensin-aldosterone system (RAAS) inhibitors corresponds to the recommended one, but there is a high frequency of prescribing angiotensin II receptor blockers (ARBs). The prescription rate of β-blockers and loop diuretics (mainly torasemide) increased in comparison with previous studies, while thiazide diuretics — decreased. In patients with reduced EF, the prescription rate of sacubitril/valsartan was only 14,7%, β-blockers — 83,3%, mineralocorticoid receptor antagonists (MCRA) — 72,5%. In patients with midrange EF, there was a sharp decrease in prescription rate of RAAS inhibitors, β-blockers, MCRA.Conclusion. The practical follow-up of patients with HF differs significantly from clinical guidelines. Due to inadequate pharmacotherapy, as well as insufficient noncompliance with the recommended extent of investigations, 1-year HF therapy does not lead to a pronounced improvement in the patients' class. |
| abstract_unstemmed |
Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.Material and methods. We performed the analysis of outpatient records of 1000 patients, followed up for 1 year by a general practitioner or cardiologist in ambulatory clinic in 7 Russian regions. The study included men and women over 18 years of age with an established class II-IV HF and at least one hospitalization due to acute decompensated HF within 12-month follow-up.Results. The final analysis included 888 patients (men, 52,9%; women, 47,1%; mean age, 69 [61; 78] years). The preserved ejection fraction (EF) was detected in 47,86% of patients, mid-range — in 40,54%, reduced — in 11,6%. Only in 16% of patients, there was improved by 1 or more HF. Hypertension and coronary artery disease were predominant in etiology pattern of HF. Preserved EF was more often detected in women over 60 years of age, with HTN and obesity, as well as with HF with mid-range and reduced EF in men in the same age group. There was sufficient follow-up rate, but the extent examinations do not correspond to the recommended one. The prescription rate of renin-angiotensin-aldosterone system (RAAS) inhibitors corresponds to the recommended one, but there is a high frequency of prescribing angiotensin II receptor blockers (ARBs). The prescription rate of β-blockers and loop diuretics (mainly torasemide) increased in comparison with previous studies, while thiazide diuretics — decreased. In patients with reduced EF, the prescription rate of sacubitril/valsartan was only 14,7%, β-blockers — 83,3%, mineralocorticoid receptor antagonists (MCRA) — 72,5%. In patients with midrange EF, there was a sharp decrease in prescription rate of RAAS inhibitors, β-blockers, MCRA.Conclusion. The practical follow-up of patients with HF differs significantly from clinical guidelines. Due to inadequate pharmacotherapy, as well as insufficient noncompliance with the recommended extent of investigations, 1-year HF therapy does not lead to a pronounced improvement in the patients' class. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
4 |
| title_short |
Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I |
| url |
https://doi.org/10.15829/1560-4071-2021-4368 https://doaj.org/article/69da45f5a9f2442abd4c2790d12db976 https://russjcardiol.elpub.ru/jour/article/view/4368 https://doaj.org/toc/1560-4071 https://doaj.org/toc/2618-7620 |
| remote_bool |
true |
| author2 |
S. V. Nedogoda M. V. Arkhipov A. S. Galyavich N. A. Koziolova N. G. Lozhkina E. V. Reznik A. S. Salasyuk M. Yu. Frolov A. I. Chesnikova E. V. Chumachek L. A. Shpagina |
| author2Str |
S. V. Nedogoda M. V. Arkhipov A. S. Galyavich N. A. Koziolova N. G. Lozhkina E. V. Reznik A. S. Salasyuk M. Yu. Frolov A. I. Chesnikova E. V. Chumachek L. A. Shpagina |
| ppnlink |
1760594547 |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.15829/1560-4071-2021-4368 |
| callnumber-a |
RC666-701 |
| up_date |
2024-07-03T16:24:42.206Z |
| _version_ |
1803575762306990080 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ030680166</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410123320.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2021 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.15829/1560-4071-2021-4368</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ030680166</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ69da45f5a9f2442abd4c2790d12db976</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Yu. M. Lopatin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.Material and methods. We performed the analysis of outpatient records of 1000 patients, followed up for 1 year by a general practitioner or cardiologist in ambulatory clinic in 7 Russian regions. The study included men and women over 18 years of age with an established class II-IV HF and at least one hospitalization due to acute decompensated HF within 12-month follow-up.Results. The final analysis included 888 patients (men, 52,9%; women, 47,1%; mean age, 69 [61; 78] years). The preserved ejection fraction (EF) was detected in 47,86% of patients, mid-range — in 40,54%, reduced — in 11,6%. Only in 16% of patients, there was improved by 1 or more HF. Hypertension and coronary artery disease were predominant in etiology pattern of HF. Preserved EF was more often detected in women over 60 years of age, with HTN and obesity, as well as with HF with mid-range and reduced EF in men in the same age group. There was sufficient follow-up rate, but the extent examinations do not correspond to the recommended one. The prescription rate of renin-angiotensin-aldosterone system (RAAS) inhibitors corresponds to the recommended one, but there is a high frequency of prescribing angiotensin II receptor blockers (ARBs). The prescription rate of β-blockers and loop diuretics (mainly torasemide) increased in comparison with previous studies, while thiazide diuretics — decreased. In patients with reduced EF, the prescription rate of sacubitril/valsartan was only 14,7%, β-blockers — 83,3%, mineralocorticoid receptor antagonists (MCRA) — 72,5%. In patients with midrange EF, there was a sharp decrease in prescription rate of RAAS inhibitors, β-blockers, MCRA.Conclusion. The practical follow-up of patients with HF differs significantly from clinical guidelines. Due to inadequate pharmacotherapy, as well as insufficient noncompliance with the recommended extent of investigations, 1-year HF therapy does not lead to a pronounced improvement in the patients' class.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pharmacoepidemiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">left ventricular ejection fraction</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">functional class</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. V. Nedogoda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. V. Arkhipov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. S. Galyavich</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. A. Koziolova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. G. Lozhkina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Reznik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. S. Salasyuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Yu. Frolov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. I. Chesnikova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Chumachek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. A. Shpagina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Российский кардиологический журнал</subfield><subfield code="d">«FIRMA «SILICEA» LLC, 2019</subfield><subfield code="g">26(2021), 4</subfield><subfield code="w">(DE-627)1760594547</subfield><subfield code="x">26187620</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.15829/1560-4071-2021-4368</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/69da45f5a9f2442abd4c2790d12db976</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://russjcardiol.elpub.ru/jour/article/view/4368</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1560-4071</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-7620</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield></datafield></record></collection>
|
| score |
7.402011 |